SPDR S&P Biotech (XBI) 67.77 $XBI Biotech ETFs in Focus

New Post Public Reply Private Reply Replies (0) Message Board

Sep 26, 2016 at 7:11 PM

SPDR S&P Biotech (XBI) 67.77 $XBI

Biotech ETFs in Focus on Tobira Therapeutics' Massive Gain
Sanghamitra Saha - Zacks Investment Research - Wed Sep 21, 10:23AM CDT
Tobira Therapeutics surged following the news that Allergan is buying it at an astounding premium and drove several biotech ETFs higher.
BBP: 33.97 (-0.41), AGN: 238.68 (-5.26), SBIO: 26.78 (-0.53), BBC: 22.89 (-0.16), GLMD: 5.30 (+0.08), XBI: 67.77 (-0.37), CNAT: 2.10 (-0.01), ICPT: 166.02 (-0.21), IBB: 294.53 (-3.65)

You Can’t Ignore the Biotech Breakout
Greg Guenthner - Daily Reckoning - Tue Sep 20, 8:46AM CDT
This post You Can’t Ignore the Biotech Breakout appeared first on Daily Reckoning . The major averages couldn’t hold onto their morning gains yesterday. Stocks spent the day slowly sinking into the red. But that didn’t stop a surprise FDA...
XBI: 67.77 (-0.37), SRPT: 59.66 (+1.83), PTCT: 11.64 (-0.02)

Biotechnology ETFs Rally on Sarepta FDA Drug Approval
editor@etftrends.com (ETF Trends) - ETF Trends - Mon Sep 19, 3:09PM CDT
Sarepta Therapeutics (NasdaqGS: SRPT) surged Monday and lifted biotechnology-related exchange traded funds after the Food and Drug Administration approved the Duchenne muscular dystrophy drug eteplirsen. Leading the charge in the ETF space on Monday,...
BBC: 22.89 (-0.16), XBI: 67.77 (-0.37), PTH: 53.39 (-0.22), IBB: 294.53 (-3.65)

SPDR S&P Biotech ETF Rises 2.72% on Heavy Volume: Watch For Potential Pullback
Comtex SmarTrend(R) - Mon Sep 19, 11:55AM CDT
SPDR S&P Biotech ETF (AMEX:XBI) traded in a range yesterday that spanned from a low of $64.53 to a high of $67.48. Yesterday, the shares gained 2.7%, which took the trading range above the 3-day high of $65.10 on volume of 5.4 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
XBI: 67.77 (-0.37)

Inside the Recent Surge in Biotech ETFs
Sanghamitra Saha - Zacks Investment Research - Wed Sep 14, 1:19PM CDT
What caused biotech ETFs to tack on solid gains on September 12.
PBE: 42.69 (-0.68), SBIO: 26.78 (-0.53), PRGO: 95.73 (-1.67), RPTP: 8.96 (-0.04), GILD: 80.62 (-0.75), FBT: 100.98 (-0.90), XBI: 67.77 (-0.37), FOMX: 9.83 (-0.37), HZNP: 18.82 (-0.61), IBB: 294.53 (-3.65)

SmarTrend Watching for Potential Pullback in Shares of SPDR S&P Biotech ETF After 2.13% Gain
Comtex SmarTrend(R) - Wed Sep 14, 12:14PM CDT
SPDR S&P Biotech ETF (AMEX:XBI) traded in a range yesterday that spanned from a low of $62.65 to a high of $64.54. Yesterday, the shares gained 2.1%, which took the trading range above the 3-day high of $63.46 on volume of 2.9 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
XBI: 67.77 (-0.37)

Watch for SPDR S&P Biotech ETF to Potentially Pullback After Gaining 2.88% Yesterday
Comtex SmarTrend(R) - Tue Sep 06, 2:46PM CDT
SPDR S&P Biotech ETF (AMEX:XBI) traded in a range yesterday that spanned from a low of $60.68 to a high of $61.99. Yesterday, the shares gained 2.9%, which took the trading range above the 3-day high of $60.94 on volume of 2.1 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
XBI: 67.77 (-0.37)

Biotech ETF Industry Outlook
Zacks Equity Research - Zacks Investment Research - Wed Aug 31, 2:39PM CDT
It has been a challenging environment for the biotech industry so far; how are these ETFs expected to perform for the rest of 2016.
PBE: 42.69 (-0.68), FBT: 100.98 (-0.90), XBI: 67.77 (-0.37), BBH: 117.02 (-1.55), IBB: 294.53 (-3.65)

After Yesterday's Decline of 1.56%, SPDR S&P Biotech ETF Offers Investors Better Value
Comtex SmarTrend(R) - Wed Aug 31, 12:25PM CDT
SPDR S&P Biotech ETF (AMEX:XBI) traded in a range yesterday that spanned from a low of $59.79 to a high of $60.94. Yesterday, the shares fell 1.6%, which took the trading range below the 3-day low of $60.17 on volume of 2.8 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
XBI: 67.77 (-0.37)

Healthcare ETFs Need Some Rest
editor@etftrends.com (ETF Trends) - ETF Trends - Wed Aug 31, 9:48AM CDT
It has not been a typical year for healthcare exchange traded funds such as the Vanguard Health Care ETF (NYSEArca: VHT) and the Health Care Select Sector SPDR (NYSEArca: XLV). Political posturing has been weighing on the S&P 500’s...
XBI: 67.77 (-0.37), IBB: 294.53 (-3.65), VHT: 133.21 (-1.55), XLV: 72.26 (-0.85)

10 Most Read ETF Articles of the Week (August 22-26)
editor@etftrends.com (ETF Trends) - ETF Trends - Fri Aug 26, 5:42PM CDT
Each day, ETFtrends.com publishes news, strategy and commentary on ETFs in the realms of Commodities, Currency, Equities and Smart-Beta to name a few. Here’s a look at the 10 most read articles of the week on ETF Trends, Aug. 22-26, 2016. Click the...
HYG: 86.38 (-0.38), USO: 10.43 (+0.24), GDXS: 15.55 (+0.25), GDJS: 1.90 (-0.10), XBI: 67.77 (-0.37), BNO: 13.85 (+0.29), IBB: 294.53 (-3.65), ZBIO: 20.22 (+0.71), XLV: 72.26 (-0.85), JNK: 36.35 (-0.16), BIS: 30.54 (+0.72), DUST: 32.67 (+0.83), XLF: 19.07 (-0.31), GDX: 26.78 (-0.24), LABD: 16.28 (+0.21), VHT: 133.21 (-1.55), JDST: 23.39 (+0.77)

Biotech ETFs in Focus After Mylan's EpiPen Controversy
Sanghamitra Saha - Zacks Investment Research - Fri Aug 26, 9:27AM CDT
Mylan offers discounts to the purchase of EpiPen to cool down criticism over its steep price. How will biotech ETFs take this move?
GNRX: 24.86 (-0.43), XBI: 67.77 (-0.37), MYL: 41.18 (-0.88), IBB: 294.53 (-3.65)

Pfizer Acquires Medivation, Renews Biotech M&A Bets
editor@etftrends.com (ETF Trends) - ETF Trends - Mon Aug 22, 1:20PM CDT
Pfizer (NYSE: PFE) announced a $14 billion deal to acquire cancer drug developer Medivation (NasdaqGS: MDVN), propelling the broader biotechnology exchange traded funds higher on speculation of more deals in the sector. Biopharmaceutical giant Pfizer...
PBE: 42.69 (-0.68), SBIO: 26.78 (-0.53), BBC: 22.89 (-0.16), XBI: 67.77 (-0.37)

Another Endorsement for Biotech ETFs
editor@etftrends.com (ETF Trends) - ETF Trends - Tue Aug 16, 10:30AM CDT
The iShares Nasdaq Biotechnology ETF (NasdaqGS: IBB), which tracks the Nasdaq Biotechnology Index, and rival biotechnology exchange traded funds, seem to have put the woes experienced earlier this year behind them and recently have been in rally...
FBT: 100.98 (-0.90), XBI: 67.77 (-0.37), IBB: 294.53 (-3.65)

After Yesterday's Rally of 1.73% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Mon Aug 15, 12:42PM CDT
SPDR S&P Biotech ETF (AMEX:XBI) traded in a range yesterday that spanned from a low of $62.72 to a high of $63.61. Yesterday, the shares gained 1.7%, which took the trading range above the 3-day high of $62.77 on volume of 2.8 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
XBI: 67.77 (-0.37)

SmarTrend Watching for Potential Rebound in Shares of SPDR S&P Biotech ETF After 2.50% Loss
Comtex SmarTrend(R) - Wed Aug 10, 12:10PM CDT
SPDR S&P Biotech ETF (AMEX:XBI) traded in a range yesterday that spanned from a low of $60.93 to a high of $62.77. Yesterday, the shares fell 2.5%, which took the trading range below the 3-day low of $62.39 on volume of 4.0 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
XBI: 67.77 (-0.37)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Trial Disappointment: No Significant Gains in NSCLC

Dissecting the Nuances of the EVOKE-03/KEYNOTE-D46 Trial Every once in a while, we come across a trial that rattles cages in the research community. Today, it's the EVOKE-03/KEYNOTE-D46 trial, a collision of hope and hard-knock reality. This Phase 3 trial, which sought to explore the potential combo of sacituzumab govitecan (SG) and pembrolizumab on metastatic non-small...

GORGIE Unleashes Berry Burst: Target's New Drink Star

GORGIE Targets Taste Buds with Berry Burst Ever feel like you're missing out on that energy drink everyone seems to be raving about? Well, GORGIE's out there making some noise again, and this time it's got a new punchy player in the game: Berry Burst. It's not just another drink; it's shaking things up in the energy aisle with its exclusive launch at Target. Modern style...

Surfing Dogs Ride Waves, Support Orphan Pets

Waves, Paws, and Passion Who would've thought that dogs catching waves could also catch hearts and wallets? Well, that's exactly what's happening today at Del Mar Dog Beach with the 21st Annual Surf Dog Surf-A-Thon revving up the excitement. It's a sun-soaked day in Rancho Santa Fe, California, right in the thick of things at the longest-running dog surf competition. For...

First-Time Homeowners: Unseen Pitfalls of Insurance

Understanding Homeowners Insurance: Beyond the Basics Most folks diving into homeownership for the first time get caught up in the whirlwind of price tags, loans, and knick-knacks for their new place. Meanwhile, the nitty-gritty of homeowners insurance often gets tossed to the side. But take it from a weary watchdog of financial storms—it’s those details in the policy...

Regeneron Faces Legal Heat: Lead Plaintiff Deadline Looms

Regeneron’s Tight Spot: Legal Showdown Well, here we go again—Regeneron Pharmaceuticals (NASDAQ:REGN) is under some serious heat. If you're an investor who faced significant losses with this biotech juggernaut, remember that the clock’s ticking down to the wire. By tomorrow, September 14, 2026, you need to decide if you're going to throw your hat in the ring for...

Ris-Rez May Set New Standard in Relapsed SCLC

The Game-Changing Results Innovation in pharmaceuticals sometimes feels like a waiting game, but when a fresh breakthrough like this rolls in, it lights up the whole landscape. Risvutatug rezetecan, or Ris-Rez for short, has shown promising potential in the fight against relapsed small-cell lung cancer (SCLC) that has progressed after platinum-based therapy. Survival...

PANDAG G1 Debuts: Revolutionizing Lawn Care Efficiency

The Future of Landscaping Unveiled Get this—PANDAG is set to shake things up at GaLaBau 2026 with their futuristic G1 autonomous mower. This isn't just another piece of lawn equipment; it's practically a tech marvel on wheels, weaving together LiDAR, AI Vision, RTK, and 4G tech to make it the ultimate multitasker for the landscaping industry. We're talking obstacle...

PwC US and India Unite for Global Consultancy Powerhouse

Rearranging the Consultancy Chessboard Piling onto the game of consultancy realignments, PwC just made a move reminiscent of playing strategy poker. They're tossing together PwC US and PwC India's advisory capabilities for a new joint venture. It’s like pushing two puzzle pieces to make a single colorful picture that stretches from the U.S. all the way to the...

MRI Surveillance Gains Ground in Lung Cancer Care

Shifting the Standard: MRI's Rise in SCLC Treatment Here's a twist that baffles the traditionalists—ditch the prophylactic cranial irradiation (PCI) and catch clearer days with MRI surveillance for small-cell lung cancer (SCLC). The latest international phase III MAVERICK trial might just redraw the lines on what's considered standard care in this relentless disease....

UWM Faces Class Action Deadline: Key Insights for Investors

The High Stakes Reality for UWM Investors If there's one thing that's certain in this jittery world of investing, it's that losses have a way of waking you up. Right now, anyone tied up with UWM Holdings Corporation (NYSE: UWMC) shares needs to keep their wits about them; we're barreling toward an October 13, 2026 deadline for a class action lawsuit. The clock's ticking...